论文部分内容阅读
目的:利用荧光原位杂交技术(fluorescent in situ hybridazation,FISH)评估膀胱肿瘤术(TURBT)预后效果。方法:选取2011年6月到2012年12月50例膀胱肿瘤病人。患者均术前排除上尿路泌尿系肿瘤,手术方式为经尿道膀胱肿瘤电切术(TURBT),术后接受规律膀胱内灌注(灌注药物为表柔比星)治疗。FISH检测的时间为TURBT术前,术后一周,术后三月,术后半年。结果:FISH检测中阳性细胞百分率随手术及术后膀胱灌注表柔比星总体呈逐渐下降趋势。其中术前与术后一周,FISH阳性细胞百分率变化具有统计学意义(P<0.001)。术后一周与术后三月FISH阳性细胞百分率比较,具有统计学意义(P<0.001)。术后三月至术后半年的FISH检测阳性细胞百分率下降不明显(P=0.148)。FISH阳性细胞百分率越高肿瘤复发机率越高,FISH阳性细胞百分率≥25%者与<25%者肿瘤复发率有统计学意义(P<0.001)。结论:手术和术后定期膀胱灌注可以明显降低术后三月的尿阳性细胞百分率。术后FISH阳性细胞百分率≥25%者的肿瘤复发率明显高于<25%的患者。
Objective: To evaluate the prognosis of bladder tumor surgery (TURBT) by fluorescence in situ hybridization (FISH). Methods: Fifty patients with bladder cancer from June 2011 to December 2012 were selected. Patients were excluded from the urinary tract urinary tract surgery before surgery for the transurethral resection of the bladder tumor (TURBT), after intravesical instillation of perfusion (perfusion drug epirubicin) treatment. FISH detection time TURBT before surgery, one week after surgery, three months after surgery, six months after surgery. Results: The percentage of positive cells in FISH assay gradually decreased with the surgery and postoperative intravesical instillation of epirubicin. The percentages of FISH positive cells in preoperative and postoperative one week were statistically significant (P <0.001). The percentage of positive FISH cells in one week after surgery was statistically significant (P <0.001). The percentage of positive FISH cells detected from March to 6 months after surgery was not significantly decreased (P = 0.148). The higher the percentage of FISH positive cells, the higher the probability of tumor recurrence, the percentage of FISH positive cells ≥25% and <25% were statistically significant (P <0.001). Conclusion: Regular intravesical instillation of bladder after surgery and surgery can significantly reduce the percentage of urine-positive cells in three months after operation. Postoperative FISH positive cell percentage> 25% of the tumor recurrence rate was significantly higher than <25% of patients.